Clinical Trial

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic…

4 weeks ago

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy…

4 weeks ago

Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

4 weeks ago

NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, Nov. 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the…

4 weeks ago

Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,…

4 weeks ago

Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic

NORTHAMPTON, MA / ACCESSWIRE / November 26, 2024 / Women - especially teen girls and young women living in sub-Saharan…

4 weeks ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billions…

4 weeks ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular…

4 weeks ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~~ Expects Early Interim Data in 1Q 2025 ~ SAN DIEGO, CA…

4 weeks ago

Cannabix Technologies Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settingsVANCOUVER, British…

4 weeks ago